NCT03448835

Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)

Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Non-metastatic, Resectable Gastric and GE-junction Cancer: The PANDA Trial

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: The Netherlands Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this explorative study, patients with resectabel cancer of the stomach or stomach-oesophagealjunction cancer will receive neoadjuvant treatment. The treatment will be 1 cyle atzolizumab monotherapy, followed by 4 cycle of atezolizumab and capecitabine, oxaliplatin and docetaxel.

Detailed description

In this single-centre, open-label, monocenter study, the investigators will enroll 20 patients with resectable cancer of the stomach of GEJunction. All patients will be treated with 1 cycle of atezolizumab monotherapy, followed by 4 cycles of combinationtherapy of atezolizumab, capecitabine, oxaliplatin and docetaxel, followed by surgery.

Conditions

• Stomach Cancer
• Gastro Esophageal Junction Cancer

Interventions

Type	Name	Description
DRUG	Atezolizumab	atezolizumab 1200 mg 5 cycles
DRUG	Capecitabine	capecitabine 850 mg /m2 4 cycles
DRUG	Oxaliplatin	oxaliplatin 100 mg/m2 4 cycles
DRUG	Docetaxel	docetaxel 50 mg/m2 4 cycles

Timeline

• Start date: 2018-03-07
• Primary completion: 2026-10-31
• Completion: 2026-10-31
• First posted: 2018-02-28
• Last updated: 2025-06-08

Locations

2 sites across 1 country: Netherlands